How Big Will the SpaceX IPO Be?
Operated up to now as a private business, SpaceX will…
Sell
30
OM Quote, Financials, Valuation and Earnings
Last price:
$4.49
Seasonality move
:
-7.87%
Day range:
$4.32 - $4.56
52-week range:
$3.10 - $21.98
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.89x
P/B ratio:
0.58x
Volume:
218.5K
Avg. volume:
1.3M
1-year change:
-62.5%
Market cap:
$79.9M
Revenue:
$113.7M
EPS (TTM):
-$13.00
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
OM
Outset Medical, Inc.
|
$28.9M | -$0.68 | -1.68% | -79.35% | $11.75 |
|
ABT
Abbott Laboratories
|
$11.8B | $1.49 | 6.13% | 54.83% | $133.11 |
|
ARAY
Accuray, Inc.
|
$100.9M | -$0.11 | -1.19% | -296.83% | $2.53 |
|
BSX
Boston Scientific Corp.
|
$5.3B | $0.78 | 11.4% | 75.76% | $106.78 |
|
CATX
Perspective Therapeutics, Inc.
|
$232.5K | -$0.35 | -57.02% | -42.52% | $13.0000 |
|
PSTV
Plus Therapeutics, Inc.
|
$1.2M | -$0.04 | 22.78% | -97.49% | $5.50 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
OM
Outset Medical, Inc.
|
$4.50 | $11.75 | $79.9M | -- | $0.00 | 0% | 0.89x |
|
ABT
Abbott Laboratories
|
$110.83 | $133.11 | $192.7B | 29.93x | $0.63 | 2.17% | 4.37x |
|
ARAY
Accuray, Inc.
|
$0.62 | $2.53 | $70.3M | 149.00x | $0.00 | 0% | 0.16x |
|
BSX
Boston Scientific Corp.
|
$76.27 | $106.78 | $113.1B | 39.33x | $0.00 | 0% | 5.68x |
|
CATX
Perspective Therapeutics, Inc.
|
$4.7100 | $13.0000 | $350.1M | -- | $0.00 | 0% | 319.36x |
|
PSTV
Plus Therapeutics, Inc.
|
$0.26 | $5.50 | $35.7M | -- | $0.00 | 0% | 4.17x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
OM
Outset Medical, Inc.
|
40.94% | 4.147 | 38.74% | 5.74x |
|
ABT
Abbott Laboratories
|
20.25% | 0.141 | -- | 1.12x |
|
ARAY
Accuray, Inc.
|
76.53% | 1.394 | 186.42% | 0.52x |
|
BSX
Boston Scientific Corp.
|
33.99% | 0.200 | -- | 0.81x |
|
CATX
Perspective Therapeutics, Inc.
|
1.35% | 2.996 | 1.3% | 8.47x |
|
PSTV
Plus Therapeutics, Inc.
|
0.41% | -1.387 | 0.02% | 1.22x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
OM
Outset Medical, Inc.
|
$11.6M | -$15.8M | -35.38% | -81.05% | -53.73% | -$6.5M |
|
ABT
Abbott Laboratories
|
$6.5B | $2.4B | 10.2% | 29.06% | 20.59% | $2.3B |
|
ARAY
Accuray, Inc.
|
$24.1M | -$5.5M | -14.23% | -60.6% | -5.37% | $8.4M |
|
BSX
Boston Scientific Corp.
|
$3.7B | $1B | 8.4% | 12.46% | 19.69% | $1.2B |
|
CATX
Perspective Therapeutics, Inc.
|
-$566K | -$27.9M | -37.13% | -37.63% | -13330.62% | -$18.3M |
|
PSTV
Plus Therapeutics, Inc.
|
$1.3M | -$4.5M | -- | -- | -320.83% | -$2.6M |
Outset Medical, Inc. vs. Competitors
-
Which has Higher Returns OM or ABT?
Abbott Laboratories has a net margin of -60.61% compared to Outset Medical, Inc.'s net margin of 15.5%. Outset Medical, Inc.'s return on equity of -81.05% beat Abbott Laboratories's return on equity of 29.06%.
Company Gross Margin Earnings Per Share Invested Capital OMOutset Medical, Inc.39.38% -$1.00 $241M ABTAbbott Laboratories57.09% $1.02 $64.2B -
What do Analysts Say About OM or ABT?
Outset Medical, Inc. has a consensus price target of $11.75, signalling upside risk potential of 161.11%. On the other hand Abbott Laboratories has an analysts' consensus of $133.11 which suggests that it could grow by 20.11%. Given that Outset Medical, Inc. has higher upside potential than Abbott Laboratories, analysts believe Outset Medical, Inc. is more attractive than Abbott Laboratories.
Company Buy Ratings Hold Ratings Sell Ratings OMOutset Medical, Inc.3 0 0 ABTAbbott Laboratories15 7 0 -
Is OM or ABT More Risky?
Outset Medical, Inc. has a beta of 2.079, which suggesting that the stock is 107.879% more volatile than S&P 500. In comparison Abbott Laboratories has a beta of 0.749, suggesting its less volatile than the S&P 500 by 25.138%.
-
Which is a Better Dividend Stock OM or ABT?
Outset Medical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Abbott Laboratories offers a yield of 2.17% to investors and pays a quarterly dividend of $0.63 per share. Outset Medical, Inc. pays -- of its earnings as a dividend. Abbott Laboratories pays out 64.34% of its earnings as a dividend. Abbott Laboratories's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios OM or ABT?
Outset Medical, Inc. quarterly revenues are $29.4M, which are smaller than Abbott Laboratories quarterly revenues of $11.5B. Outset Medical, Inc.'s net income of -$17.8M is lower than Abbott Laboratories's net income of $1.8B. Notably, Outset Medical, Inc.'s price-to-earnings ratio is -- while Abbott Laboratories's PE ratio is 29.93x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Outset Medical, Inc. is 0.89x versus 4.37x for Abbott Laboratories. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income OMOutset Medical, Inc.0.89x -- $29.4M -$17.8M ABTAbbott Laboratories4.37x 29.93x $11.5B $1.8B
-
Which has Higher Returns OM or ARAY?
Accuray, Inc. has a net margin of -60.61% compared to Outset Medical, Inc.'s net margin of -13.47%. Outset Medical, Inc.'s return on equity of -81.05% beat Accuray, Inc.'s return on equity of -60.6%.
Company Gross Margin Earnings Per Share Invested Capital OMOutset Medical, Inc.39.38% -$1.00 $241M ARAYAccuray, Inc.23.54% -$0.11 $227.6M -
What do Analysts Say About OM or ARAY?
Outset Medical, Inc. has a consensus price target of $11.75, signalling upside risk potential of 161.11%. On the other hand Accuray, Inc. has an analysts' consensus of $2.53 which suggests that it could grow by 307.26%. Given that Accuray, Inc. has higher upside potential than Outset Medical, Inc., analysts believe Accuray, Inc. is more attractive than Outset Medical, Inc..
Company Buy Ratings Hold Ratings Sell Ratings OMOutset Medical, Inc.3 0 0 ARAYAccuray, Inc.2 0 0 -
Is OM or ARAY More Risky?
Outset Medical, Inc. has a beta of 2.079, which suggesting that the stock is 107.879% more volatile than S&P 500. In comparison Accuray, Inc. has a beta of 1.151, suggesting its more volatile than the S&P 500 by 15.124%.
-
Which is a Better Dividend Stock OM or ARAY?
Outset Medical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Accuray, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Outset Medical, Inc. pays -- of its earnings as a dividend. Accuray, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios OM or ARAY?
Outset Medical, Inc. quarterly revenues are $29.4M, which are smaller than Accuray, Inc. quarterly revenues of $102.2M. Outset Medical, Inc.'s net income of -$17.8M is lower than Accuray, Inc.'s net income of -$13.8M. Notably, Outset Medical, Inc.'s price-to-earnings ratio is -- while Accuray, Inc.'s PE ratio is 149.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Outset Medical, Inc. is 0.89x versus 0.16x for Accuray, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income OMOutset Medical, Inc.0.89x -- $29.4M -$17.8M ARAYAccuray, Inc.0.16x 149.00x $102.2M -$13.8M
-
Which has Higher Returns OM or BSX?
Boston Scientific Corp. has a net margin of -60.61% compared to Outset Medical, Inc.'s net margin of 12.68%. Outset Medical, Inc.'s return on equity of -81.05% beat Boston Scientific Corp.'s return on equity of 12.46%.
Company Gross Margin Earnings Per Share Invested Capital OMOutset Medical, Inc.39.38% -$1.00 $241M BSXBoston Scientific Corp.69.58% $0.45 $35.7B -
What do Analysts Say About OM or BSX?
Outset Medical, Inc. has a consensus price target of $11.75, signalling upside risk potential of 161.11%. On the other hand Boston Scientific Corp. has an analysts' consensus of $106.78 which suggests that it could grow by 40%. Given that Outset Medical, Inc. has higher upside potential than Boston Scientific Corp., analysts believe Outset Medical, Inc. is more attractive than Boston Scientific Corp..
Company Buy Ratings Hold Ratings Sell Ratings OMOutset Medical, Inc.3 0 0 BSXBoston Scientific Corp.26 0 0 -
Is OM or BSX More Risky?
Outset Medical, Inc. has a beta of 2.079, which suggesting that the stock is 107.879% more volatile than S&P 500. In comparison Boston Scientific Corp. has a beta of 0.666, suggesting its less volatile than the S&P 500 by 33.441%.
-
Which is a Better Dividend Stock OM or BSX?
Outset Medical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Boston Scientific Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Outset Medical, Inc. pays -- of its earnings as a dividend. Boston Scientific Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios OM or BSX?
Outset Medical, Inc. quarterly revenues are $29.4M, which are smaller than Boston Scientific Corp. quarterly revenues of $5.3B. Outset Medical, Inc.'s net income of -$17.8M is lower than Boston Scientific Corp.'s net income of $670M. Notably, Outset Medical, Inc.'s price-to-earnings ratio is -- while Boston Scientific Corp.'s PE ratio is 39.33x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Outset Medical, Inc. is 0.89x versus 5.68x for Boston Scientific Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income OMOutset Medical, Inc.0.89x -- $29.4M -$17.8M BSXBoston Scientific Corp.5.68x 39.33x $5.3B $670M
-
Which has Higher Returns OM or CATX?
Perspective Therapeutics, Inc. has a net margin of -60.61% compared to Outset Medical, Inc.'s net margin of -12425.36%. Outset Medical, Inc.'s return on equity of -81.05% beat Perspective Therapeutics, Inc.'s return on equity of -37.63%.
Company Gross Margin Earnings Per Share Invested Capital OMOutset Medical, Inc.39.38% -$1.00 $241M CATXPerspective Therapeutics, Inc.-270.81% -$0.35 $245.5M -
What do Analysts Say About OM or CATX?
Outset Medical, Inc. has a consensus price target of $11.75, signalling upside risk potential of 161.11%. On the other hand Perspective Therapeutics, Inc. has an analysts' consensus of $13.0000 which suggests that it could grow by 176.01%. Given that Perspective Therapeutics, Inc. has higher upside potential than Outset Medical, Inc., analysts believe Perspective Therapeutics, Inc. is more attractive than Outset Medical, Inc..
Company Buy Ratings Hold Ratings Sell Ratings OMOutset Medical, Inc.3 0 0 CATXPerspective Therapeutics, Inc.11 1 0 -
Is OM or CATX More Risky?
Outset Medical, Inc. has a beta of 2.079, which suggesting that the stock is 107.879% more volatile than S&P 500. In comparison Perspective Therapeutics, Inc. has a beta of 1.747, suggesting its more volatile than the S&P 500 by 74.695%.
-
Which is a Better Dividend Stock OM or CATX?
Outset Medical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Outset Medical, Inc. pays -- of its earnings as a dividend. Perspective Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios OM or CATX?
Outset Medical, Inc. quarterly revenues are $29.4M, which are larger than Perspective Therapeutics, Inc. quarterly revenues of $209K. Outset Medical, Inc.'s net income of -$17.8M is higher than Perspective Therapeutics, Inc.'s net income of -$26M. Notably, Outset Medical, Inc.'s price-to-earnings ratio is -- while Perspective Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Outset Medical, Inc. is 0.89x versus 319.36x for Perspective Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income OMOutset Medical, Inc.0.89x -- $29.4M -$17.8M CATXPerspective Therapeutics, Inc.319.36x -- $209K -$26M
-
Which has Higher Returns OM or PSTV?
Plus Therapeutics, Inc. has a net margin of -60.61% compared to Outset Medical, Inc.'s net margin of -316.61%. Outset Medical, Inc.'s return on equity of -81.05% beat Plus Therapeutics, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital OMOutset Medical, Inc.39.38% -$1.00 $241M PSTVPlus Therapeutics, Inc.93.84% -$0.04 $5.1M -
What do Analysts Say About OM or PSTV?
Outset Medical, Inc. has a consensus price target of $11.75, signalling upside risk potential of 161.11%. On the other hand Plus Therapeutics, Inc. has an analysts' consensus of $5.50 which suggests that it could grow by 2016.2%. Given that Plus Therapeutics, Inc. has higher upside potential than Outset Medical, Inc., analysts believe Plus Therapeutics, Inc. is more attractive than Outset Medical, Inc..
Company Buy Ratings Hold Ratings Sell Ratings OMOutset Medical, Inc.3 0 0 PSTVPlus Therapeutics, Inc.4 0 0 -
Is OM or PSTV More Risky?
Outset Medical, Inc. has a beta of 2.079, which suggesting that the stock is 107.879% more volatile than S&P 500. In comparison Plus Therapeutics, Inc. has a beta of 0.886, suggesting its less volatile than the S&P 500 by 11.364%.
-
Which is a Better Dividend Stock OM or PSTV?
Outset Medical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Plus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Outset Medical, Inc. pays -- of its earnings as a dividend. Plus Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios OM or PSTV?
Outset Medical, Inc. quarterly revenues are $29.4M, which are larger than Plus Therapeutics, Inc. quarterly revenues of $1.4M. Outset Medical, Inc.'s net income of -$17.8M is lower than Plus Therapeutics, Inc.'s net income of -$4.4M. Notably, Outset Medical, Inc.'s price-to-earnings ratio is -- while Plus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Outset Medical, Inc. is 0.89x versus 4.17x for Plus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income OMOutset Medical, Inc.0.89x -- $29.4M -$17.8M PSTVPlus Therapeutics, Inc.4.17x -- $1.4M -$4.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will ISRG Stock Be in 5 Years?
Intuitive Surgical (NASDAQ:ISRG) is the innovative medical tech business behind…
Is Kratos Stock a Good Investment?
UAV and hypersonic system defense contractor Kratos (NASDAQ:KTOS) has swung…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
53
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 30x
Alerts
Sell
40
BILL alert for Feb 7
Bill Holdings, Inc. [BILL] is up 37.11% over the past day.
Buy
75
PRLB alert for Feb 7
Proto Labs, Inc. [PRLB] is up 28.33% over the past day.
Sell
30
MSTR alert for Feb 7
Strategy, Inc. [MSTR] is up 26.08% over the past day.
